{"date":"2026-05-25","count":42,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6734-2026-05-25-2020-lwss1b","company_id":"6734","company":"安盛生","market":"興櫃","industry":"生技醫療","date":"2026-05-25","time":"20:20:17","subject":"公告本公司訂定現金增資發行新股認股基準日等相關事宜","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：安盛生（6734），2026-05-25 20:20，「公告本公司訂定現金增資發行新股認股基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-05-25-1935-1s5kymp","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"19:35:50","subject":"代子公司霖揚生技製藥股份有限公司公告更換董事","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-05-25 19:35，「代子公司霖揚生技製藥股份有限公司公告更換董事」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4726-2026-05-25-1929-11aiibo","company_id":"4726","company":"永昕","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"19:29:06","subject":"公告本公司股東會通過同意解除董事及其代表人競業禁止之限制案","clause":"第21款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：永昕（4726），2026-05-25 19:29，「公告本公司股東會通過同意解除董事及其代表人競業禁止之限制案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4726-2026-05-25-1928-1jb8ii5","company_id":"4726","company":"永昕","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"19:28:24","subject":"公告本公司115年股東常會重要決議事項","clause":"第18款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：永昕（4726），2026-05-25 19:28，「公告本公司115年股東常會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-05-25-1909-1x3ky28","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"19:09:08","subject":"代子公司英屬開曼群島商霖揚藥業股份有限公司公告更換董事","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-05-25 19:09，「代子公司英屬開曼群島商霖揚藥業股份有限公司公告更換董事」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-05-25-1908-1su03io","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"19:08:47","subject":"公告本公司執行長異動","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-05-25 19:08，「公告本公司執行長異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-05-25-1908-3w8zkz","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"19:08:26","subject":"公告本公司薪資報酬委員會召集人","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-05-25 19:08，「公告本公司薪資報酬委員會召集人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-05-25-1908-1ymdye0","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"19:08:03","subject":"公告本公司審計委員會召集人","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-05-25 19:08，「公告本公司審計委員會召集人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-05-25-1907-1e8qqmm","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"19:07:39","subject":"調整本公司位於美國之子公司組織架構及人力配置","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-05-25 19:07，「調整本公司位於美國之子公司組織架構及人力配置」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-05-25-1907-jh76i1","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"19:07:17","subject":"本公司擬主動撤回向美國FDA提出Pegargiminase(ADI-PEG 20)生物製劑用於治療惡性胸膜間皮瘤之上市許可證申請案(BLA)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-05-25 19:07，「本公司擬主動撤回向美國FDA提出Pegargiminase(ADI-PEG 20)生物製劑用於治療惡性胸膜間皮瘤之上市許」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2026-05-25-1906-l3ir5g","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"19:06:56","subject":"本公司決議暫緩ADI-PEG 20治療LMS三期人體臨床試驗","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2026-05-25 19:06，「本公司決議暫緩ADI-PEG 20治療LMS三期人體臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-05-25-1832-r4wx6f","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"18:32:00","subject":"公告本公司股票創新板初次第一上市前現金增資員工認購股款催繳事宜。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-05-25 18:32，「公告本公司股票創新板初次第一上市前現金增資員工認購股款催繳事宜。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4138-2026-05-25-1826-1gh8rmj","company_id":"4138","company":"曜亞","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"18:26:12","subject":"代重要子公司曜胜生技股份有限公司公告董事會推選新任董事長","clause":"第6款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：曜亞（4138），2026-05-25 18:26，「代重要子公司曜胜生技股份有限公司公告董事會推選新任董事長」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4138-2026-05-25-1824-nunvgd","company_id":"4138","company":"曜亞","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"18:24:50","subject":"代重要子公司曜胜生技股份有限公司公告股東會決議通過解除董事競業禁止之限制案","clause":"第21款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：曜亞（4138），2026-05-25 18:24，「代重要子公司曜胜生技股份有限公司公告股東會決議通過解除董事競業禁止之限制案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4138-2026-05-25-1823-4ab19s","company_id":"4138","company":"曜亞","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"18:23:51","subject":"代重要子公司曜胜生技股份有限公司公告股東會之決議事項","clause":"第18款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：曜亞（4138），2026-05-25 18:23，「代重要子公司曜胜生技股份有限公司公告股東會之決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6637-2026-05-25-1814-fn5aok","company_id":"6637","company":"醫影","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"18:14:42","subject":"本公司受邀參加富邦證券舉辦之法人說明會","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：醫影（6637），2026-05-25 18:14，「本公司受邀參加富邦證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2026-05-25-1759-15y9fgi","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"17:59:55","subject":"本公司115年股東常會解除董事(含獨立董事)競業禁止之限制案(更正年度)","clause":"第21款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2026-05-25 17:59，「本公司115年股東常會解除董事(含獨立董事)競業禁止之限制案(更正年度)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4147-2026-05-25-1739-m9k8dq","company_id":"4147","company":"中裕","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"17:39:40","subject":"公告本公司115年股東常會決議解除董事競業禁止限制","clause":"第21款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：中裕（4147），2026-05-25 17:39，「公告本公司115年股東常會決議解除董事競業禁止限制」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3118-2026-05-25-1733-1wbzcpx","company_id":"3118","company":"進階","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"17:33:44","subject":"公告本公司114年度除息基準日","clause":"第14款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：進階（3118），2026-05-25 17:33，「公告本公司114年度除息基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3118-2026-05-25-1733-cobe39","company_id":"3118","company":"進階","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"17:33:11","subject":"公告本公司115年股東常會重要決議","clause":"第18款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：進階（3118），2026-05-25 17:33，「公告本公司115年股東常會重要決議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-05-25-1704-g74uyy","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"17:04:51","subject":"代子公司新和生物科技(股)公司公告董事會決議不分配股利","clause":"第14款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-05-25 17:04，「代子公司新和生物科技(股)公司公告董事會決議不分配股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-05-25-1704-q8qmdk","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"17:04:36","subject":"代子公司九和生物科技(股)公司公告董事會決議分配股利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-05-25 17:04，「代子公司九和生物科技(股)公司公告董事會決議分配股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-05-25-1704-1sb5ivn","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"17:04:21","subject":"代子公司東霖儀器(股)公司公告董事會決議分配股利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-05-25 17:04，「代子公司東霖儀器(股)公司公告董事會決議分配股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-05-25-1704-1lw30zy","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"17:04:05","subject":"代子公司醫世紀健康管理顧問(股)公司公告董事會決議分配股利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-05-25 17:04，「代子公司醫世紀健康管理顧問(股)公司公告董事會決議分配股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-05-25-1703-12iu88x","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"17:03:49","subject":"代子公司華霖(股)公司公告董事會決議分配股利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-05-25 17:03，「代子公司華霖(股)公司公告董事會決議分配股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-05-25-1703-1jew7bo","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"17:03:33","subject":"代子公司九和科技(股)公司公告董事會決議分配股利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-05-25 17:03，「代子公司九和科技(股)公司公告董事會決議分配股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-05-25-1703-1eilj9q","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"17:03:13","subject":"代子公司多模式(股)公司公告董事會決議分配股利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-05-25 17:03，「代子公司多模式(股)公司公告董事會決議分配股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-05-25-1702-10ybqwd","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"17:02:45","subject":"代重要子公司杏業生技(股)公司公告董事會決議分配股利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-05-25 17:02，「代重要子公司杏業生技(股)公司公告董事會決議分配股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-05-25-1702-132muta","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"17:02:08","subject":"代重要子公司久和醫療儀器(股)公司公告董事會決議分配股利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-05-25 17:02，「代重要子公司久和醫療儀器(股)公司公告董事會決議分配股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6986-2026-05-25-1652-q7wryr","company_id":"6986","company":"和迅","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"16:52:57","subject":"本公司將於115年5月29日舉辦上櫃前業績發表會","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：和迅（6986），2026-05-25 16:52，「本公司將於115年5月29日舉辦上櫃前業績發表會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4771-2026-05-25-1649-1jb8ii5","company_id":"4771","company":"望隼","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"16:49:47","subject":"公告本公司115年股東常會重要決議事項","clause":"第18款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：望隼（4771），2026-05-25 16:49，「公告本公司115年股東常會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6857-2026-05-25-1602-1jb8ii5","company_id":"6857","company":"宏碁智醫","market":"興櫃","industry":"生技醫療","date":"2026-05-25","time":"16:02:32","subject":"公告本公司115年股東常會重要決議事項","clause":"第15款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：宏碁智醫（6857），2026-05-25 16:02，「公告本公司115年股東常會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2026-05-25-1555-5lyx9v","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"15:55:25","subject":"本公司114年股東常會解除董事(含獨立董事)競業禁止之限制案","clause":"第21款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2026-05-25 15:55，「本公司114年股東常會解除董事(含獨立董事)競業禁止之限制案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2026-05-25-1554-cobe39","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"15:54:34","subject":"公告本公司115年股東常會重要決議","clause":"第18款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2026-05-25 15:54，「公告本公司115年股東常會重要決議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1760-2026-05-25-1534-34ha9q","company_id":"1760","company":"寶齡富錦","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"15:34:44","subject":"公告本公司現金股利發放公告","clause":"第14款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：寶齡富錦（1760），2026-05-25 15:34，「公告本公司現金股利發放公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4147-2026-05-25-1529-1jb8ii5","company_id":"4147","company":"中裕","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"15:29:04","subject":"公告本公司115年股東常會重要決議事項","clause":"第18款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：中裕（4147），2026-05-25 15:29，「公告本公司115年股東常會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1760-2026-05-25-1526-ss0ao7","company_id":"1760","company":"寶齡富錦","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"15:26:40","subject":"公告本公司股東常會通過解除董事及其代表人競業禁止之限制","clause":"第21款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：寶齡富錦（1760），2026-05-25 15:26，「公告本公司股東常會通過解除董事及其代表人競業禁止之限制」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1760-2026-05-25-1526-1jb8ii5","company_id":"1760","company":"寶齡富錦","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"15:26:06","subject":"公告本公司115年股東常會重要決議事項","clause":"第18款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：寶齡富錦（1760），2026-05-25 15:26，「公告本公司115年股東常會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4117-2026-05-25-1517-1xu8svj","company_id":"4117","company":"普生","market":"興櫃","industry":"生技醫療","date":"2026-05-25","time":"15:17:03","subject":"公告本公司115年04月份自結合併財務報告之負債比率、流動比率及速動比率","clause":"第44款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：普生（4117），2026-05-25 15:17，「公告本公司115年04月份自結合併財務報告之負債比率、流動比率及速動比率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7799-2026-05-25-1500-b8cobr","company_id":"7799","company":"禾榮科","market":"上市","industry":"生技醫療","date":"2026-05-25","time":"15:00:11","subject":"本公司研發之B10 L-BPA 注射液向台灣衛生福利部食品藥物管理署(TFDA)提出復發性局部晚期或轉移性三陰性乳癌之學術研究用人體臨床試驗審查申請(IND)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：禾榮科（7799），2026-05-25 15:00，「本公司研發之B10 L-BPA 注射液向台灣衛生福利部食品藥物管理署(TFDA)提出復發性局部晚期或轉移性三陰性乳癌之學」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2026-05-25-1413-pnu9hw","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"14:13:48","subject":"公告本公司收到「NALTREXONE INJECTABLE SUSTAINEDRELEASE FORMULATION」加拿大專利核准通知書。","clause":"第53款","fact_date":"2026-05-25","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2026-05-25 14:13，「公告本公司收到「NALTREXONE INJECTABLE SUSTAINEDRELEASE FORMULATION」加」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4123-2026-05-25-1346-1k5ssj5","company_id":"4123","company":"晟德","market":"上櫃","industry":"生技醫療","date":"2026-05-25","time":"13:46:56","subject":"本公司受邀參加統一證券舉辦之全球展望夏季投資論壇","clause":"第12款","fact_date":"2026-05-29","cite_as":"公開資訊觀測站重大訊息：晟德（4123），2026-05-25 13:46，「本公司受邀參加統一證券舉辦之全球展望夏季投資論壇」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}